ImClone Revenue and Competitors
Estimated Revenue & Valuation
- ImClone's estimated annual revenue is currently $73.3M per year.
- ImClone's estimated revenue per employee is $155,000
Employee Data
- ImClone has 473 Employees.
- ImClone grew their employee count by 0% last year.
ImClone's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Global Clinical Pharmacology | Reveal Email/Phone |
2 | Associate VP, Regulatory Affairs | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | Associate Director, Quality Control | Reveal Email/Phone |
5 | Manager, Financial Reporting and Analysis | Reveal Email/Phone |
6 | Facilities Manager | Reveal Email/Phone |
7 | QA Auditing Manager | Reveal Email/Phone |
8 | Manager, Quality Assurance Auditing | Reveal Email/Phone |
9 | Sr. Manager | Reveal Email/Phone |
10 | Manager, Clinical Affairs | Reveal Email/Phone |
ImClone Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ImClone?
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
keywords:N/A
N/A
Total Funding
473
Number of Employees
$73.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ImClone News
ImClone Systems (Eli Lilly). This comprehensive Targeted Drug VEGFR2 Inhibitors for NSCLC Market report helps in determining the deficiencies and problems...
Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global...
... Current Therapies, Emerging Drugs, and Treatment Outlook | Companies ImClone, BeiGene, Novartis, Harbour BioMed, Tessa Therapeutics.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $85.7M | 473 | 6% | N/A |
#2 | $35M | 473 | N/A | N/A |
#3 | $134.8M | 473 | 25% | N/A |
#4 | $145.2M | 474 | -4% | N/A |
#5 | $119.1M | 474 | 23% | N/A |